20
Participants
Start Date
August 31, 2007
Primary Completion Date
November 30, 2008
Study Completion Date
December 31, 2008
Imatinib
All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.
Imatinib
Up to 600 mg QD PO for up to 1 year.
UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
University of California, Los Angeles
OTHER